MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ is a non-viral microfluidic platform for highly effective delivery of external cargos such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator™ technology enables high […]

Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class of medicines that combine the advantages of traditional small-molecule drugs and larger protein therapeutics. In a paper published in Cell in September 2022 titled “Accurate […]

CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not the genome of a healthy cell thereby conferring target selectivity. It is uniquely directed towards knocking out genetic pathways to allow for a broad-based combinatorial […]

THERAtRAME was founded based on new insights in transfer RNA (tRNA) epitranscriptomics resulting from over a decade of fundamental research at the GIGA Institute (ULiège) and WELBIO. Transfer RNAs mediate the translation of the genetic information (mRNAs) into cellular effectors (proteins). Chemical modifications of tRNA molecules promote cellular adaptation through reprogramming of protein expression, playing […]

NEOsphere Biotechnologies is a German biotech startup that has developed a proteomic platform for systematic identification of novel targets for targeted protein degradation. NEOsphere uses cutting-edge mass spectrometry technology to screen libraries of tens of thousands of compounds against proteomes of more than 10,000 proteins. Using purpose-built data processing the company systematically extracts high-probability candidates […]

Founded in 2021, Epigenic Therapeutics is a Chinese startup developing next generation gene editing therapies for a wide variety of diseases, using modulation of the epigenetic genome. Epigenic Therapeutics’ proprietary technology platform employs artificial intelligence algorithms to explore and obtain an optimized CRISPR-Cas component to regulate target gene(s) or govern the expression of one or […]

hC Bioscience is developing Transfer RNA-based therapeutics targeting protein dysfunction. Transfer RNA (tRNA) is a small RNA molecule that plays a key role in protein synthesis. tRNA serves as a link (or adaptor) between the messenger RNA (mRNA) molecule and the growing chain of amino acids that make up a protein. Each time an amino […]

Melius Pharma is a Swedish company founded in 2021 focused on the development of new treatments for interstitial lung diseases. The company’s lead project for chronic cough in idiopathic pulmonary fibrosis is set to enter a Phase IIa clinical proof of concept study. Chronic cough is a serious symptom in idiopathic pulmonary fibrosis that severely […]

Therorna was founded in China in 2021, leveraging its proprietary circular RNA technology platform to develop next-generation vaccines and innovative therapies. Compared with linear RNA, circular RNA (circRNA) offers benefits in expression, stability, immunogenicity, and production. Thanks to its structure, circRNA as a tool for protein expression has been proven to maintain a relatively stable […]

Tamarix Pharma was founded in 2021 based on technology licensed from the National Institute for Biotechnology in the Negev (Israel) and is focused on developing novel technologies that restore physiological balance in apoptosis-related diseases. The company’s lead assets, VBIT-4 and VBIT-12, are small molecules designed to target a key mitochondrial process known as VDAC1 oligomerization. […]

BacVax is a spin-off from the University of Arizona with a novel approach to developing vaccines against bacterial infections by mapping the proteins on the surface of bacteria. BacVax’s approach involves bioinformatic analyses of genome sequences paired with protein structure analysis to identify protein regions that are: present in every strain in the species; on […]

Lento Bio was founded in 2022 in collaboration with Ichor Life Sciences and Clarkson University’s Shipley Center for Innovation, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage. The company’s primary focus is the removal of Advanced Glycation End Products (AGEs), […]

Oravax Medical is developing proprietary technologies for the oral delivery of vaccines. The company was founded in 2021 as a joint venture between Oramed Pharmaceuticals, using its proprietary POD™ oral delivery technology and Premas Biotech, with its novel vaccine technology. Due to the inherent hurdles presented by the digestive system, an exceptionally small fraction of […]

Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 is often described as a “double-edged sword” because of its ability both to suppress and activate the immune system. For cancer patients, increased levels of IL-2 correlate with improved survival. […]

Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and Duchenne Muscular Dystrophy. Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with delivery of genetic […]

Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Parkinson’s. These disorders impact memory, movement, language, behavior, and personality resulting in disability and death of millions of patients. […]

Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by several orders of magnitude. No technology currently exists that can sequence the amino acids of proteins at a single molecule level. To change this, Glyphic is developing a next generation […]

ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID’s aiSPIRE platform screens billions of antibody-target interactions while concurrently applying AI to reveal the history of immune responses in each patient. ImmuneID combines this proprietary data with deep patient-specific clinical findings and private and public […]

Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation and mutations.  Transcription factors (TFs) have long been the aspirational targets of drug developers, based on their central role in cancer and other diseases. TFs are DNA-binding proteins that can […]

Shoreline Biosciences is developing genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and macrophage cellular immunotherapies that are intelligently designed for greater potency and persistence, to create safe, effective, and affordable immunotherapies for the treatment of seriously ill patients. Shoreline’s proprietary cell therapy platform is based on deep expertise in iPSC differentiation […]